title: Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.
authors.affiliation: Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Elena B
authors.identifier: http://orcid.org/0000-0002-4294-8460
authors.initials: EB
authors.lastname: Volokhina
authors.affiliation: Research Laboratory, Nordland Hospital, Bodø, Norway.
authors.forename: Grethe
authors.initials: G
authors.lastname: Bergseth
authors.affiliation: Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Nicole C A J
authors.initials: NC
authors.lastname: van de Kar
authors.affiliation: Department of Pediatric Nephrology, and Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands Department of Pediatric Nephrology, University Hospitals, Leuven, Belgium.
authors.forename: Lambertus P
authors.initials: LP
authors.lastname: van den Heuvel
authors.affiliation: Research Laboratory, Nordland Hospital, Bodø, Norway Department of Immunology, Oslo University Hospital, K.G. Jebsen Inflammation Research Centre, University of Oslo, Oslo, Norway Faculty of Health Sciences, K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, Tromsø, Norway Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway.
authors.forename: Tom Eirik
authors.initials: TE
authors.lastname: Mollnes
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015936:Complement C5a / Q000276:immunology*; D005260:Female; D017359:HELLP Syndrome / Q000628:therapy*; D006801:Humans; D011247:Pregnancy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015936:Complement C5a